Redeye endorses OssDsign's advancement in its clinical study for Catalyst (TOP FUSION), as the first of 17 patients has been enrolled. We still expect first sales to be generated in the US for said product this year but emphasize that adding clinical data supports its chances of a more successful and broader commercialization in the longer term.